Works matching DE "ERLOTINIB"
Results: 1010
Design, Synthesis, In Vitro Anticancer and ADMET Studies of Piperazine-Pyrazolo-Quinoxalin-2(1H)-one Conjugate as EGFR Targeting Agents.
- Published in:
- Russian Journal of General Chemistry, 2025, v. 95, n. 1, p. 184, doi. 10.1134/S1070363224610366
- By:
- Publication type:
- Article
Identification of erlotinib adsorption pattern onto silver nanoparticles: SERS studies.
- Published in:
- Journal of Raman Spectroscopy, 2018, v. 49, n. 8, p. 1265, doi. 10.1002/jrs.5384
- By:
- Publication type:
- Article
Predicting Blood–Brain Barrier Permeation of Erlotinib and JCN037 by Molecular Simulation.
- Published in:
- Journal of Membrane Biology, 2023, v. 256, n. 2, p. 147, doi. 10.1007/s00232-022-00274-6
- By:
- Publication type:
- Article
A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.
- Published in:
- Histochemistry & Cell Biology, 2014, v. 142, n. 4, p. 361, doi. 10.1007/s00418-014-1223-0
- By:
- Publication type:
- Article
Erlotinib and gefitinib responsiveness in head and neck cancer cell lines-a comparing analysis with cetuximab.
- Published in:
- Clinical Oral Investigations, 2016, v. 20, n. 4, p. 759, doi. 10.1007/s00784-015-1566-5
- By:
- Publication type:
- Article
Arsenic trioxide and Erlotinib loaded in RGD‐modified nanoliposomes for targeted combination delivery to PC3 and PANC‐1 cell lines.
- Published in:
- Biotechnology & Applied Biochemistry, 2023, v. 70, n. 2, p. 811, doi. 10.1002/bab.2401
- By:
- Publication type:
- Article
Combination of two miRNAs has a stronger effect on stimulating apoptosis, inhibiting cell growth, and increasing erlotinib sensitivity relative to single miRNA in A549 lung cancer cells.
- Published in:
- Biotechnology & Applied Biochemistry, 2022, v. 69, n. 4, p. 1383, doi. 10.1002/bab.2211
- By:
- Publication type:
- Article
Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy.
- Published in:
- JMIR Research Protocols, 2024, v. 13, p. 1, doi. 10.2196/51381
- By:
- Publication type:
- Article
How combination therapies shape drug resistance in heterogeneous tumoral populations.
- Published in:
- Letters in Biomathematics, 2018, v. 5, p. S160, doi. 10.1080/23737867.2018.1465862
- By:
- Publication type:
- Article
Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 9, p. 1, doi. 10.1093/jnci/dju204
- By:
- Publication type:
- Article
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 7, p. 1, doi. 10.1093/jnci/dju151
- By:
- Publication type:
- Article
Coumarin-Piperazine Tethered 1,2,3-Triazoles: EGFR Targeting Anti-Breast Cancer Evaluation and Molecular Docking Studies.
- Published in:
- Polycyclic Aromatic Compounds, 2024, v. 44, n. 8, p. 5487, doi. 10.1080/10406638.2023.2265026
- By:
- Publication type:
- Article
Synthesis of 4-Azaindole-Thiazolidine-2,4-Dione Coupled 1,2,3-Triazoles as EGFR Directing Anticancer Agents.
- Published in:
- Polycyclic Aromatic Compounds, 2024, v. 44, n. 8, p. 5009, doi. 10.1080/10406638.2023.2259563
- By:
- Publication type:
- Article
Organocatalytic [3 + 2] Cycloaddition Reaction: Synthesis of Fully Decorated Sulfonyl-1,2,3-Triazolyl Pyrimidines as Potent Anticancer and EGFR Inhibitors.
- Published in:
- Polycyclic Aromatic Compounds, 2024, v. 44, n. 4, p. 2675, doi. 10.1080/10406638.2023.2220864
- By:
- Publication type:
- Article
Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2024, v. 39, n. 1, p. 1, doi. 10.1080/14756366.2024.2311157
- By:
- Publication type:
- Article
Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2024, v. 39, n. 1, p. 1, doi. 10.1080/14756366.2024.2305856
- By:
- Publication type:
- Article
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2022, v. 37, n. 1, p. 1196, doi. 10.1080/14756366.2022.2062338
- By:
- Publication type:
- Article
Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2022, v. 37, n. 1, p. 2644, doi. 10.1080/14756366.2022.2118735
- By:
- Publication type:
- Article
Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2021, v. 36, n. 1, p. 1205, doi. 10.1080/14756366.2021.1933466
- By:
- Publication type:
- Article
Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2021, v. 36, n. 1, p. 1520, doi. 10.1080/14756366.2021.1924698
- By:
- Publication type:
- Article
Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2021, v. 36, n. 1, p. 987, doi. 10.1080/14756366.2021.1915302
- By:
- Publication type:
- Article
Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2020, v. 35, n. 1, p. 1331, doi. 10.1080/14756366.2020.1780228
- By:
- Publication type:
- Article
Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2020, v. 35, n. 1, p. 344, doi. 10.1080/14756366.2019.1702653
- By:
- Publication type:
- Article
Novel sulfonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2019, v. 34, n. 1, p. 1030, doi. 10.1080/14756366.2019.1609469
- By:
- Publication type:
- Article
Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2019, v. 34, n. 1, p. 838, doi. 10.1080/14756366.2019.1593160
- By:
- Publication type:
- Article
Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2019, v. 34, n. 1, p. 532, doi. 10.1080/14756366.2018.1564046
- By:
- Publication type:
- Article
Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2017, v. 32, n. 1, p. 1229, doi. 10.1080/14756366.2017.1368504
- By:
- Publication type:
- Article
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma.
- Published in:
- Cell Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41421-022-00425-y
- By:
- Publication type:
- Article
Immunotherapies in Development for Pancreatic Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 76
- Publication type:
- Article
Updates from ASCO 2014 and ESMO 2014.
- Published in:
- Personalized Medicine in Oncology, 2015, v. 4, n. 1, p. 23
- Publication type:
- Article
The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/6679082
- By:
- Publication type:
- Article
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy.
- Published in:
- Brain Sciences (2076-3425), 2024, v. 14, n. 12, p. 1192, doi. 10.3390/brainsci14121192
- By:
- Publication type:
- Article
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression.
- Published in:
- Biomolecules (2218-273X), 2020, v. 10, n. 4, p. 545, doi. 10.3390/biom10040545
- By:
- Publication type:
- Article
Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.01070
- By:
- Publication type:
- Article
SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00586
- By:
- Publication type:
- Article
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00132
- By:
- Publication type:
- Article
Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00030
- By:
- Publication type:
- Article
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 109, doi. 10.2147/LCTT.S119644
- By:
- Publication type:
- Article
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics.
- Published in:
- Lung Cancer: Targets & Therapy, 2014, v. 5, p. 73, doi. 10.2147/LCTT.S50671
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Comparative Assessment between Palliative Radiotherapy with Concurrent Erlotinib and Radiotherapy Alone in Advanced and/or Metastatic Non-Small Cell Lung Cancer.
- Published in:
- Basic & Clinical Cancer Research, 2023, v. 15, n. 3, p. 187
- By:
- Publication type:
- Article
From "Glivec®" to "Prevnar 13®": How strong is the Indian drug patenting system?
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Cutaneous Side Effects During Therapy With Erlotinib - Case Report.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Exploration of Nanomedicine-Based Dry Powder Inhalation Formulation Co-Loaded with Erlotinib and Curcumin for Treatment of Non-Small Cell Lung Cancer.
- Published in:
- Nano Life, 2025, v. 15, n. 2, p. 1, doi. 10.1142/S1793984424500144
- By:
- Publication type:
- Article
The SMAC mimetic AT-101 exhibits anti-tumor and antimetastasis activity in lung adenocarcinoma cells by the IAPs/caspase-dependent apoptosis and p65-NFκB cross-talk.
- Published in:
- Iranian Journal of Basic Medical Sciences, 2021, v. 24, n. 7, p. 969, doi. 10.22038/ijbms.2021.56400.12586
- By:
- Publication type:
- Article
Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.
- Published in:
- Application of Clinical Genetics, 2017, v. 10, p. 49, doi. 10.2147/TACG.S103471
- By:
- Publication type:
- Article
High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019.
- Published in:
- Clinical Epidemiology, 2021, v. 13, p. 1085, doi. 10.2147/CLEP.S332776
- By:
- Publication type:
- Article
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Published in:
- Acta Haematologica, 2018, v. 140, n. 1, p. 30, doi. 10.1159/000490092
- By:
- Publication type:
- Article